SFDA approved the registration of Anktiva for selected bladder and lung cancer indications | iPharmaCenter
Saudi Food and Drug Authority (SFDA) has approved the registration of Anktiva (nogapendekin alfa inbakicept) for selected bladder and lung cancer indications, introducing a new immunotherapy option for patients with limited treatment choices. Under the new authorization, Anktiva may be used for adult patients with metastatic non‑small cell lung cancer whose disease has progressed after standard systemic therapies, in combination with immune checkpoint inhibitors. SFDA has als
FDA clears one‑minute subcutaneous mosunetuzumab for heavily pretreated follicular lymphoma | iPharmaCenter
The US Food and Drug Administration has authorised a new under‑the‑skin version of the CD20xCD3 bispecific antibody mosunetuzumab for adults with relapsed or refractory follicular lymphoma after two or more previous systemic treatments. This subcutaneous regimen, known as Lunsumio VELO, received accelerated approval based on phase I/II data from the GO29781 trial, with continued approval potentially dependent on confirmation of clinical benefit in a follow‑up study. iPharmaCe
China Approves Myqorzo and Redemplo, Expanding Options in Hypertrophic Cardiomyopathy and Familial Chylomicronaemia Syndrome | iPharmaCenter
China’s National Medical Products Administration has authorised two innovative therapies licensed by Sanofi, strengthening treatment options in serious cardiovascular and lipid disorders. Myqorzo (aficamten) has been approved for adults with obstructive hypertrophic cardiomyopathy, while Redemplo (plozasiran) has been cleared to reduce triglyceride levels in adults with familial chylomicronaemia syndrome who require dietary management. iPharmaCenter Consulting: Find services
Lilly’s Sofetabart Mipitecan Wins FDA Breakthrough Tag in Tough‑to‑Treat Ovarian Cancer | iPharmaCenter
Lilly has disclosed that the U.S. Food and Drug Administration has granted Breakthrough Therapy status to sofetabart mipitecan (LY4170156) for adults with platinum‑resistant epithelial ovarian, fallopian tube or primary peritoneal cancer whose disease has already been treated with bevacizumab and, where appropriate, mirvetuximab soravtansine. iPharmaCenter Consulting: Find services here The investigational therapy is an antibody-drug conjugate directed against folate receptor
Top 10 pharmaceutical companies by revenues | 2025 | iPharmaCenter
Top pharmaceutical companies by revenues in 2025. The revenues are captured from the official websites of pharmaceutical companies
Aspect Biosystems Deepens Novo Nordisk Alliance to Advance Curative Cell Therapies for Diabetes | iPharmaCenter
Aspect Biosystems and Novo Nordisk have agreed to expand and reshape their existing collaboration to accelerate the development of cell‑based therapies intended to transform the treatment of diabetes. The updated agreement marks a move into a new phase of the partnership, with Aspect assuming broader control of core programmes and Novo Nordisk contributing additional technologies, capabilities and funding. Also read: Top selling drugs | 2026 The companies have been working to